In the last trading session, 2.19 million TG Therapeutics Inc (NASDAQ:TGTX) shares changed hands as the company’s beta touched 2.21. With the company’s per share price at $23.39 changed hands at -$0.44 or -1.85% during last session, the market valuation stood at $3.62B. TGTX’s last price was a discount, traded about -12.91% off its 52-week high of $26.41. The share price had its 52-week low at $6.46, which suggests the last value was 72.38% up since then. When we look at TG Therapeutics Inc’s average trading volume, we note the 10-day average is 5.96 million shares, with the 3-month average coming to 3.63 million.

Analysts gave the TG Therapeutics Inc (TGTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.56. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TGTX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. TG Therapeutics Inc’s EPS for the current quarter is expected to be 0.02.

TG Therapeutics Inc (NASDAQ:TGTX) trade information

Instantly TGTX was in red as seen at the end of in last trading. With action 0.60%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 36.94%, with the 5-day performance at 0.60% in the green. However, in the 30-day time frame, TG Therapeutics Inc (NASDAQ:TGTX) is -0.51% down. Looking at the short shares, we see there were 29.84 million shares sold at short interest cover period of 8.96 days.

The consensus price target for the stock as assigned by Wall Street analysts is 23, meaning bulls need a downside of -1.7% from its current market value. According to analyst projections, TGTX’s forecast low is 16 with 49 as the target high. To hit the forecast high, the stock’s price needs a -109.49% plunge from its current level, while the stock would need to tank 31.59% for it to hit the projected low.

TG Therapeutics Inc (TGTX) estimates and forecasts

Data shows that the TG Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 58.36% over the past 6 months, a 44.44% in annual growth rate that is considerably higher than the industry average of 12.60%. Year-over-year growth is forecast to reach 40.50% up from the last financial year.

Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 81.23M. 7 analysts are of the opinion that TG Therapeutics Inc’s revenue for the current quarter will be 98.42M. The company’s revenue for the corresponding quarters a year ago was 46.56M and 43.97M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 74.50%. The estimates for the next quarter sales put growth at 123.80%.

The 2024 estimates are for TG Therapeutics Inc earnings to decrease by -41.67%.

TGTX Dividends

TG Therapeutics Inc is expected to release its next quarterly earnings report in November.

TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 9.59% of TG Therapeutics Inc shares while 61.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 67.52%. There are 61.04% institutions holding the TG Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.3645% of the shares, roughly 13.69 million TGTX shares worth $243.58 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.7891% or 11.39 million shares worth $202.6 million as of 2024-06-30.